13F Pro quality score
Rank #2,870 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Co-Diagnostics, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $622.5K | $-46.9M | — |
| FY 2024 | 10-K | $3.9M | $-37.6M | — |
| FY 2023 | 10-K | $6.8M | $-35.3M | — |
| FY 2022 | 10-K | $34.2M | $-14.2M | -78.8% |
| FY 2021 | 10-K | $97.9M | $36.7M | 47.1% |
| FY 2020 | 10-K | $74.6M | $42.5M | 55.9% |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Co-Diagnostics, Inc. (CODX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CODX at 10.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,870 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Co-Diagnostics, Inc. reports quarterly revenue of $166.1K, net income of $-6.3M, free cash flow of $-7.2M. Top institutional holders of CODX by reported 13-F value include ARMISTICE CAPITAL, JANE STREET GROUP, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CODX trades on the Nasdaq exchange and files with the SEC under CIK 1692415. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CODX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Co-Diagnostics, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1692415 →